Brief: Avenue Therapeutics Submits FDRR To FDA With Respect To CRLs Previously Issued Related To Its IV Tramadol NDA
29/07/2021 23:14
July 29 (Reuters) - Avenue Therapeutics Inc ATXI.O :
* AVENUE THERAPEUTICS - ON JULY 27, CO SUBMITTED FDRR TO FDA
WITH
RESPECT TO CRLS PREVIOUSLY ISSUED BY FDA TO CO RELATED TO ITS IV
TRAMADOL NDA
Source text: (https://bit.ly/3rExNBm)
Further company coverage: ATXI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Avenue Therapeutics
See all newsBrief: Axsome Therapeutics Acquires AZD7325, A Selective GABA-A Modulator For Treatment Of Epilepsy
Avenue Therapeutics Inc expected to post a loss of 57 cents a share - Earnings Preview
Brief: Avenue Therapeutics Annji Intends To Terminate License Agreement With Co
Brief: Avenue Therapeutics Receives Delist Letter From Nasdaq Under Nasdaq Listing Rule 5550(B)(1)
Avenue Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary